Tweet
Source: http://www.cidrap.umn.edu/news-persp...an-may-24-2017
News Scan for May 24, 2017
Qatar MERS case; Pneumonia vaccine protection
Filed Under:
MERS-CoV; Pneumonia
Another MERS case confirmed in Qatar
The Qatari Ministry of Health reported another case of MERS-CoV detected in the country, the country's third case this year, according to a story today in The Peninsula, a Qatari daily.
The patient is a 29-year-old man who worked directly with camels, a known risk factor for contracting Middle East respiratory syndrome coronavirus (MERS-CoV). According to the Ministry of Health, the man had complained of a fever and cough for several weeks. He is hospitalized in stable condition.
Since 2012, there have been 21 cases of MERS in Qatar, 7 of them fatal. The previous cases this year were reported in March and in April.
May 24 Peninsula story
Study: Pneumococcal vaccine not effective against general pneumonia
A meta-analysis of 33 studies of the 23-valent pneumococcal vaccine (PPV23) found moderate vaccine effectiveness (VE) against pneumococcal community-acquired pneumonia (CAP) but little evidence for protection against any type of CAP (any-CAP), according to a study yesterday in PLoS One.
European investigators identified 1,159 unique papers and included 33 high-quality studies in their review. They found that VE against hospitalization for pneumococcal CAP ranged from 32% to 51% in the general population.
Against hospitalization against any-CAP, however, VE was a statistically non-significant 10% in the general population, and it varied widely in certain groups. Among those 65 years and older, for example, any-CAP VE ranged from -143% to 60%. The researchers found some evidence of protection against those vaccinated less than 60 months previously but added, "However, these results should be interpreted cautiously due to the high influence of two studies."
They concluded, "Overall, PPV23 was not consistently demonstrated to be effective in protecting against any-CAP in the general population, although some evidence for short-term vaccine effectiveness exists.
"This lack of consistency may be related to a great diversity of study populations, circulation of [Streptococcus] pneumoniae serotypes, [and] coverage of pneumococcal pediatric vaccination. . . . Monitoring of adult pneumococcal VE should continue in the context of increasing [13-strain pneumococcal conjugate vaccine] use in adults and increasing vaccination coverage in the pediatric population."
May 23 PLoS One meta-analysis
News Scan for May 24, 2017
Qatar MERS case; Pneumonia vaccine protection
Filed Under:
MERS-CoV; Pneumonia
Another MERS case confirmed in Qatar
The Qatari Ministry of Health reported another case of MERS-CoV detected in the country, the country's third case this year, according to a story today in The Peninsula, a Qatari daily.
The patient is a 29-year-old man who worked directly with camels, a known risk factor for contracting Middle East respiratory syndrome coronavirus (MERS-CoV). According to the Ministry of Health, the man had complained of a fever and cough for several weeks. He is hospitalized in stable condition.
Since 2012, there have been 21 cases of MERS in Qatar, 7 of them fatal. The previous cases this year were reported in March and in April.
May 24 Peninsula story
Study: Pneumococcal vaccine not effective against general pneumonia
A meta-analysis of 33 studies of the 23-valent pneumococcal vaccine (PPV23) found moderate vaccine effectiveness (VE) against pneumococcal community-acquired pneumonia (CAP) but little evidence for protection against any type of CAP (any-CAP), according to a study yesterday in PLoS One.
European investigators identified 1,159 unique papers and included 33 high-quality studies in their review. They found that VE against hospitalization for pneumococcal CAP ranged from 32% to 51% in the general population.
Against hospitalization against any-CAP, however, VE was a statistically non-significant 10% in the general population, and it varied widely in certain groups. Among those 65 years and older, for example, any-CAP VE ranged from -143% to 60%. The researchers found some evidence of protection against those vaccinated less than 60 months previously but added, "However, these results should be interpreted cautiously due to the high influence of two studies."
They concluded, "Overall, PPV23 was not consistently demonstrated to be effective in protecting against any-CAP in the general population, although some evidence for short-term vaccine effectiveness exists.
"This lack of consistency may be related to a great diversity of study populations, circulation of [Streptococcus] pneumoniae serotypes, [and] coverage of pneumococcal pediatric vaccination. . . . Monitoring of adult pneumococcal VE should continue in the context of increasing [13-strain pneumococcal conjugate vaccine] use in adults and increasing vaccination coverage in the pediatric population."
May 23 PLoS One meta-analysis